NCT05303701View on ClinicalTrials.gov

GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

750

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions

Moderate to Severe Alzheimer's Disease

Interventions

DRUG

GV1001 Placebo

0.9% normal saline

DRUG

GV1001 1.12mg

Lyophilized peptide from hTERT

All Listed Sponsors

lead

Samsung Pharmaceutical Co., Ltd.

INDUSTRY